CDC STACKS serves as an archival repository of CDC-published products including scientific findings, journal articles, guidelines, recommendations, or other public health information authored or co-authored by CDC or funded partners.
As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.
i
Weight gain and metabolic effects in persons with HIV who switch to ART regimens containing integrase inhibitors or tenofovir alafenamide
-
1 01 2023
-
-
Source: J Acquir Immune Defic Syndr. 92(1):67-75
[PDF-384.81 KB]
Details:
-
Alternative Title:J Acquir Immune Defic Syndr
-
Personal Author:
-
Description:Background:
The timing and magnitude of antiretroviral therapy-associated weight change attributions are unclear.
Setting:
HIV Outpatient Study participants.
Methods:
We analyzed 2007-2018 records of virally suppressed (VS) persons without integrase inhibitor (INSTI) experience who switched to either INSTI- or another non-INSTI-based ART, and remained VS. We analyzed BMI changes using linear mixed models (LMM), INSTI-and tenofovir alafenamide (TAF) contributions to BMI change by LMM-estimated slopes, and BMI inflection points.
Results:
Among 736 participants (5,316 person-years), 441 (60%) switched to INSTI-based ART; the remainder to non-INSTI-based ART. Mean follow-up was 7.15 years for INSTI recipients, 7.35 years for non-INSTI. Pre-switch, INSTI and non-INSTI groups had similar median BMI (26.3 versus 25.9 kg/m2, p=0.41). INSTI regimens included raltegravir (178), elvitegravir (112) and dolutegravir (143). Monthly BMI increases post-switch were greater with INSTI than non-INSTI (0.0525 versus 0.006, p<0.001). A BMI inflection point occurred eight months after switch among INSTI users; slopes were similar regardless of TAF use immediately post-switch. Among INSTI+TAF users, during eight months post-switch, 87% of BMI slope change was associated with INSTI use, 13% with TAF use; after eight months, estimated contributions were 27% and 73%, respectively. For non-INSTI+TAF, 84% of BMI gain was TAF-associated consistently post switch. Persons switching from TDF to TAF had greater BMI increases than others (p<0.001).
Conclusion:
Among VS persons who switched ART, INSTI and TAF use were independently associated with BMI increases. During eight months post-switch, BMI changes were greatest and most associated with INSTI use; afterward, gradual BMI gain was largely TAF-associated.
-
Subjects:
-
Keywords:
-
Source:
-
Pubmed ID:36150045
-
Pubmed Central ID:PMC11706360
-
Document Type:
-
Funding:
-
Volume:92
-
Issue:1
-
Collection(s):
-
Main Document Checksum:
-
Download URL:
-
File Type:
